Moderna, Inc. (NASDAQ:MRNA) ranks among the best biotech stocks to buy. Following solid trial results for Moderna, Inc.

The company's equity performance has been challenging throughout the year. Even after Wednesday's substantial advance, the stock remains down 37% year-to-date. Moderna's most recent quarterly report ...

Nike trades higher after the sneaker and athletic apparel company’s quarterly earnings beat Wall Street estimates.

Moderna stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector.

CureVac's (CVAC) mRNA innovations, strong patent portfolio, and investment potential. Learn the risks and rewards of this ...

Regeneron's revenue in the second quarter increased by 4% year over year to $3.68 billion. That's not phenomenal top-line ...

In the closing of the recent trading day, Moderna (MRNA) stood at $24.61, denoting a -4.91% move from the preceding trading day.

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the ...

In a report released today, Leah R. Cann from Brookline Capital Markets reiterated a Buy rating on Moderna, with a price target of $198.00. The company’s shares opened today at $26.72. Take advantage ...

Traders make money from short selling if the price of the stock falls and they lose if it rises ... As you can see from the chart above the percentage of shares that are sold short for Moderna has ...

In the most recent trading session, Moderna (MRNA) closed at $25.51, indicating a +2.03% shift from the previous trading day.